A PYMNTS Company

U.S.: CVS subsidiary to pay over $5M for false drug pricing data allegations

By  |  October 16, 2012

CVS Caremark Corp, a unit of CVS stores, has agreed to pay $5.25 million to settle allegations against falsely reporting information of prescription drug prices between 2007 and 2008 to the government’s Medicare program. In January this year, CVS agreed to pay $5 million to resolve similar allegations filed by the Federal Trade Commission.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Washington Post

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Related Content: Healthcare Reform and Antitrust Enforcement: Provider Consolidation Encouraged, Scrutinized

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.